Other recent partnerships in the molecular glue degrader category include Takeda's recent $1 billion-plus link-up with Degron Therapeutics, a $1.46 billion deal between Novo Nordisk and Neomorph ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback